Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) In Phase III RemIN...
Novartis announced FDA approval of Rhapsido (remibrutinib) for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines, based on the SD cohort of the Phase III RemIND trial where Rhapsido produced higher rates of complete hive resolution versus placebo by Week 12. The company reports a safety profile in SD consistent with CSU and no routine laboratory monitoring required.